Egalet has announced a collaboration agreement with Septodont, in which the company will promote Egalet's Sprix (ketorolac tromethamine) nasal spray exclusively to dentists in the U.S.
Sprix is a nonsteroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level, according to Egalet.
"Through our partnership with Septodont, we are able to broaden our commercial reach bringing Sprix nasal spray to dentists," Bob Radie, president and chief executive officer of Egalet, said in a release. Septodont will promote Sprix to dentists using its focused specialty sales force.
For full prescribing information, including a boxed warning, visit sprix.com.
